Injectable treatments & protocols

To support increased dermal thickness and improved skin firmness by initiating sustained Type I collagen production, addressing global laxity and the depletion of the dermal matrix.

PLLA micro-particles trigger a controlled, subclinical inflammatory response that signals the body to produce new Type I collagen, building a more organised collagen framework over 3 to 6 months. Because the improvement reflects the patient’s own collagen production rather than an injected volume, results develop gradually and maintain a natural integration with the surrounding tissue. For significant localised volume loss, PLLA works most effectively as part of a broader structural renewal plan that your practitioner can help you design.

To improve the appearance of fine lines, crepey texture, and dullness in the delicate periocular area and neck through cellular signalling and improved fibroblast activity.

Polynucleotides offer a suitable option for restoration in areas where skin is thinnest. By binding to A2A receptors on fibroblasts, they support tissue health and reduce oxidative stress without relying on volume to achieve their effect. They carry no risk of the Tyndall effect, the blue discolouration that can occur when certain fillers are placed too superficially in thin-skinned areas. Results are cumulative and develop over a structured course of treatments.

To support the remodelling of depressed atrophic scars by stimulating localised collagen synthesis and improving the skin’s overall regenerative capacity.

Regenerative injectables offer a biological stimulus that may help gradually improve the appearance of depressed scarring. Polynucleotides may help calm localised inflammation and support the remodelling of fibrous scar tissue, while PLLA can address broader dermal thinning associated with more significant scarring. This approach offers a non-thermal option where lasers may carry a risk of post-inflammatory hyperpigmentation in darker skin tones. It works best as part of a multi-modality plan, often following subcision, and your practitioner can advise on appropriate sequencing.

To support recovery in sensitised or inflamed skin by reducing oxidative stress and improving the cellular environment in compromised tissue.

Polynucleotides have documented anti-inflammatory properties that make them relevant for skin presenting with chronic sensitivity or a compromised barrier. By binding to A2A receptors and reducing oxidative stress markers, they may help create a more stable cellular environment in skin that is struggling to maintain its own resilience. This works best alongside appropriate clinical oversight for chronic conditions such as eczema or severe rosacea rather than as a replacement for clinical care. If your skin has felt reactive to most things, this is a conversation worth having with your practitioner.

To address skin laxity and crepey texture on larger body surface areas such as the décolletage, arms, and thighs, where dermal thinning is the primary concern.

Higher-volume PLLA applications create a widespread collagen-stimulating signal across larger body areas, which may help improve the appearance of skin laxity and surface texture over a structured course of treatments. This is not a weight-loss treatment and does not replicate the effect of a surgical lift. What it can offer is a gradual, measurable improvement in skin quality over time. I encourage you to discuss realistic expectations with your practitioner before starting a treatment course.